Adam W. Finerman

Partner

New York
T +1.212.589.4233
F +1.212.589.4201

Overview

As Co-Leader of the IPOs and Securities Offerings team, Adam Finerman utilizes his broad experience in IPOs, securities offerings, proxy contests and mergers and acquisitions to counsel public and private companies in their mergers, asset acquisitions and divestitures, stock purchase transactions, restructuring of securities, capital markets transactions and public and private common and preferred equity transactions, as well as debt financing transactions. He also advises public companies in their transactional and capital markets transactions, and on general corporate matters, SEC reporting requirements and other public company obligations.

Adam is a skilled corporate, securities and capital markets lawyer with broad experience in IPOs, securities offerings, proxy contests and mergers and acquisitions. He also advises hedge funds and investment funds on equity investments in public companies. His experience includes a number of sophisticated equity and debt offerings, public company mergers, and extensive counseling on securities disclosure, compliance with SEC and stock exchange requirements, corporate governance and investor relations matters.

Select Experience

  • Represented P10, Inc. (NYSE:PX) in $240 million initial public offering and listing on the New York Stock Exchange.
  • Represented Summit Therapeutics Inc. (Nasdaq: SMMT), a clinical-stage drug discovery and development company, in a fully-subscribed $75 million rights offering.
  • Represented Summit Therapeutics Inc. (Nasdaq:SMMT) in a sale of notes in principal amount of $55 million.
More »

Experience

  • Represented P10, Inc. (NYSE:PX) in $240 million initial public offering and listing on the New York Stock Exchange.
  • Represented Summit Therapeutics Inc. (Nasdaq: SMMT), a clinical-stage drug discovery and development company, in a fully-subscribed $75 million rights offering.
  • Represented Summit Therapeutics Inc. (Nasdaq:SMMT) in a sale of notes in principal amount of $55 million.
  • Represented a Nasdaq-listed company in the acquisition of several strategic acquisitions.
  • Represented 210 Capital, LLC, a private investment fund, in its acquisition of common stock of Support.com, Inc. (Nasdaq:SPRT).
  • Represented GlobalSCAPE, Inc. (NYSE American: GSB), a pioneer in securing and automating the movement and integration of data, in its acquisition by HelpSystems, LLC in a transaction valued at approximately $217 million.
  • Represented a Nasdaq-listed diversified holding entity with healthcare, construction and investment divisions, in public offering of common stock and warrants.
  • Represented a leading biotech investor in $75 million acquisition of common shares in Nasdaq-listed company.
  • Represented biotech drug discovery company in connection with its redomiciliation from the United Kingdom to Delaware, and listing on the Nasdaq Global Market.
  • Represented a Nasdaq-listed diversified holding entity in the sale of two divisions.
  • Represented GlobalSCAPE, Inc. (NYSE American: GSB) in $55 million secured credit facility and payment of extraordinary dividend.
  • Represented Star Equity Holdings (Nasdaq: STRR) in the acquisition of diagnostic imaging services business from private equity firm for $36 million, and in obtaining a credit facility to fund the acquisition.
  • Represented Star Equity Holdings, Inc. (Nasdaq:STRR) in its acquisition of ATRM, a modular building and construction business, in an exchange of STRR common stock for ATRM preferred stock, and STRR preferred stock for ATRM preferred stock.
  • Advised Pharmacyclics, Inc. (Nasdaq: PCYC) as special counsel on certain issues relating to PCYC’s acquisition by AbbVie Inc. for a total transaction value of $21 billion.
  • Represented Novation Companies, Inc. (OTC: NOVC) in the sale of the membership interests of Corvisa LLC, a wholly-owned subsidiary.
  • Represented ATRM Holdings, Inc. (Nasdaq: ATRM) in the sale of its test handler product line business to a wholly-owned subsidiary of Boston Semi Equipment LLC, as well as the acquisition of several modular building businesses.
  • Represented ATRM Holdings, Inc. (Nasdaq: ATRM) in the negotiation of credit facilities to fund acquisitions and to provide working capital.
  • Represented Xstelos Holdings, Inc. (formerly Footstar, Inc.) in its acquisition of CPEX Pharmaceuticals, Inc.
  • Represent the Chairman and Chief Executive Officer of a leading hospitality company in merger agreement with the company valued at approximately $1.3 billion.
  • Represent public company in plan of divestiture entailing the sale of up to four of its divisions.
  • Represented NYSE public company in its sale of a division for approximately $95 million.
  • Represented investor group in the acquisition of assets and signing of Trademark License Agreement with Phat Fashions, LLC relating to the BABY PHAT clothing line. Represented the company in a subsequent recapitalization transaction.
  • Represented a Nasdaq-listed public company in obtaining a senior secured credit facility from Wells Fargo Bank.
  • Represented Crossroads Systems, Inc. (Nasdaq: CRDS) in a litigation financing transaction.
  • Represented a healthcare media company in a corporate transaction involving a new receivables facility, the restructuring and sale of existing term loan with GE Capital and new equity investment in company.
  • Represented ATRM Holdings, Inc. (OTCQX: ATRM) in a public rights offering.
  • Represented Crossroads Systems, Inc. (Nasdaq: CRDS) in a public rights offering.
  • Represented Ameri Holdings, Inc. (OTC: AMRH) in a reverse public offering involving a reverse merger.
  • Represented Pharmacyclics Inc. in a $207.2 million overnight public offering of 2.2 million shares of its common stock.
  • Represented Pharmacyclics, Inc. in several registered direct offerings aggregating over $100 million.
  • Represent many private companies, including a start-up fashion designer, in private financing transactions.
  • Represented numerous borrowers in multimillion-dollar credit facilities.
  • Represent numerous public companies in their reporting obligations, financings and acquisitions and divestitures.
  • Represent private investment funds in their investments in numerous closed-end funds, including filing Schedule 13Ds and amendments, nominating directors, commencing proxy solicitations to elect directors and/or regarding various proposals (including in support of proposals to liquidate or commence a material tender, or in opposition to a merger).
  • Represented a private investor in its investment in iHeart Media Inc. and seeking FCC approval to purchase up to 49.99% of iHeart Media Inc.
  • Represent numerous hedge funds in proxy contests and stockholder activism with public companies.

Recognitions and Memberships

Memberships

  • Association of the Bar of the City of New York
  • The Penn Fund of the University of Pennsylvania: Executive Board

Admissions

  • New York

Education

  • J.D., University of Pennsylvania Law School, 1991
  • M.B.A., The Wharton School of the University of Pennsylvania, 1991
  • B.S.E., The Wharton School of the University of Pennsylvania, 1987, cum laude